Durable Molecular Response Despite F317L and E255K Mutations: Successful Treatment of Chronic Myeloid Leukemia With Sequential Imatinib, Nilotinib and Dasatinib

Leuk Res. 2012 Jan;36(1):e10-1. doi: 10.1016/j.leukres.2011.09.002. Epub 2011 Oct 1.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Amino Acid Substitution / physiology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzamides
  • Biomarkers, Pharmacological / analysis*
  • Biomarkers, Pharmacological / metabolism
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Dasatinib
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Glutamic Acid / genetics
  • Humans
  • Imatinib Mesylate
  • Leucine / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Lysine / genetics
  • Mutation, Missense / physiology
  • Phenylalanine / genetics
  • Piperazines / administration & dosage*
  • Polymorphism, Single Nucleotide / physiology
  • Pyrimidines / administration & dosage*
  • Remission Induction
  • Thiazoles / administration & dosage*
  • Time Factors
  • Treatment Outcome

Substances

  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
  • Benzamides
  • Biomarkers, Pharmacological
  • Biomarkers, Tumor
  • Piperazines
  • Pyrimidines
  • Thiazoles
  • Glutamic Acid
  • Phenylalanine
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Leucine
  • Lysine
  • Dasatinib